JP6526577B2 - 非酸化の生物学的に活性な副甲状腺ホルモンは血液透析患者における死亡率を決定する - Google Patents

非酸化の生物学的に活性な副甲状腺ホルモンは血液透析患者における死亡率を決定する Download PDF

Info

Publication number
JP6526577B2
JP6526577B2 JP2015560717A JP2015560717A JP6526577B2 JP 6526577 B2 JP6526577 B2 JP 6526577B2 JP 2015560717 A JP2015560717 A JP 2015560717A JP 2015560717 A JP2015560717 A JP 2015560717A JP 6526577 B2 JP6526577 B2 JP 6526577B2
Authority
JP
Japan
Prior art keywords
pth
peptide
human pth
oxidized
ipth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015560717A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016512323A (ja
JP2016512323A5 (cg-RX-API-DMAC7.html
Inventor
アルムブルステル，フランツ・パウル
ホッヘル，ベルトホルト
ロート，ハインツ・ユルゲン
Original Assignee
イムーンダイアグノスティック・アー・ゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イムーンダイアグノスティック・アー・ゲー filed Critical イムーンダイアグノスティック・アー・ゲー
Publication of JP2016512323A publication Critical patent/JP2016512323A/ja
Publication of JP2016512323A5 publication Critical patent/JP2016512323A5/ja
Application granted granted Critical
Publication of JP6526577B2 publication Critical patent/JP6526577B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/635—Parathyroid hormone (parathormone); Parathyroid hormone-related peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2015560717A 2013-03-08 2014-03-07 非酸化の生物学的に活性な副甲状腺ホルモンは血液透析患者における死亡率を決定する Active JP6526577B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13158401.3A EP2775306B1 (en) 2013-03-08 2013-03-08 Non-oxidized, biological active parathyroid hormone determines mortality in hemodialysis patients
EP13158401.3 2013-03-08
PCT/EP2014/054508 WO2014135701A1 (en) 2013-03-08 2014-03-07 Non-oxidized, biological active parathyroid hormone determines mortality in hemodialysis patients

Publications (3)

Publication Number Publication Date
JP2016512323A JP2016512323A (ja) 2016-04-25
JP2016512323A5 JP2016512323A5 (cg-RX-API-DMAC7.html) 2017-04-06
JP6526577B2 true JP6526577B2 (ja) 2019-06-05

Family

ID=47827083

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015560717A Active JP6526577B2 (ja) 2013-03-08 2014-03-07 非酸化の生物学的に活性な副甲状腺ホルモンは血液透析患者における死亡率を決定する

Country Status (6)

Country Link
US (1) US10613101B2 (cg-RX-API-DMAC7.html)
EP (1) EP2775306B1 (cg-RX-API-DMAC7.html)
JP (1) JP6526577B2 (cg-RX-API-DMAC7.html)
CA (1) CA2904433A1 (cg-RX-API-DMAC7.html)
ES (1) ES2689193T3 (cg-RX-API-DMAC7.html)
WO (1) WO2014135701A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2714565T3 (es) 2014-02-20 2019-05-29 Immundiagnostik Ag Diagnóstico in vitro y pronóstico de nefropatía inducida por contraste (nic) en pacientes sometidos a angiografía coronaria
EP3499235A1 (en) 2017-12-13 2019-06-19 Immundiagnostik AG Method of measuring auto-antibodies in bodily fluids
WO2019141791A1 (en) * 2018-01-17 2019-07-25 Immundiagnostik Ag Biomarker predicting coronary artery disease
ES2984718T3 (es) 2018-08-20 2024-10-30 Immundiagnostik Ag Composición de sorbente para el tratamiento preanalítico de muestras

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988006596A1 (en) 1987-03-02 1988-09-07 Bissendorf Peptide Gmbh New cardiodilatin fragment, process for preparing same and use thereof
CA2040264A1 (en) 1990-04-12 1991-10-13 Tatsuhiko Kanmera Parathyroid hormone antagonists
DE4434551A1 (de) 1994-09-28 1996-04-04 Forssmann Wolf Georg Prof Dr D Peptide aus der Sequenz des hPTH (1-37)
US6689566B1 (en) 1999-01-14 2004-02-10 Scantibodies Laboratory, Inc. Methods, kits, and antibodies for detecting parathyroid hormone
DE19961350A1 (de) 1999-12-17 2001-06-21 Immundiagnostik Ag Verfahren zur Bestimmung der Parathormon-Aktivität in einer menschlichen Probe
DE10116552A1 (de) * 2001-04-03 2002-10-10 Abc Armbruster Biochemicals Verfahren zur Bestimmung der wirksamen Parathormon-Aktivität in einer Probe
US20030082179A1 (en) 2001-07-03 2003-05-01 Hutchison James Scott Parathyroid hormone antibodies and related methods
EP2631247A1 (en) * 2012-02-22 2013-08-28 Immundiagnostik AG Means and methods of measuring parathyroid hormone in patients suffering from oxidative stress

Also Published As

Publication number Publication date
EP2775306A1 (en) 2014-09-10
JP2016512323A (ja) 2016-04-25
CA2904433A1 (en) 2014-09-12
WO2014135701A1 (en) 2014-09-12
EP2775306B1 (en) 2018-06-27
ES2689193T3 (es) 2018-11-08
US10613101B2 (en) 2020-04-07
US20160025748A1 (en) 2016-01-28

Similar Documents

Publication Publication Date Title
EP1151307B1 (en) Methods for differentiating and monitoring parathyroid and bone status related diseases
Friedman et al. PTH (1–84)/PTH (7–84): a balance of power
US20040265926A1 (en) Bodily fluid markers of tissue hypoxia
JP6526577B2 (ja) 非酸化の生物学的に活性な副甲状腺ホルモンは血液透析患者における死亡率を決定する
US20190100576A1 (en) Signal biomarkers
CA2865182C (en) Means and methods of measuring parathyroid hormone in patients suffering from oxidative stress
Ndrepepa De Ritis ratio and cardiovascular disease: evidence and underlying mechanisms
CA2531995A1 (en) Methods, kits and antibodies for detecting parathyroid hormone
Yamashita et al. Serum osteocalcin levels are useful as a predictor of cardiovascular events in maintenance hemodialysis patients
JP2016512323A5 (cg-RX-API-DMAC7.html)
JP4294961B2 (ja) 試料中の実効的な副甲状腺ホルモン活性の測定方法
Negrea Biochemical abnormalities in chronic kidney disease–mineral bone disease
Fellah et al. Predictors for cardiovascular morbidity and overall mortality in Tunisian ESRD patients: a six year prospective study
Gerritsen et al. Connective tissue growth factor (CTGF/CCN-2) is related to residual kidney function, previous cardiovascular disease and underlying renal disease in hemodialysis patients
den Hoedt et al. Connective tissue growth factor (CTGF/CCN-2) is related to residual kidney function, previous cardiovascular disease and underlying renal disease in hemodialysis patients
CN1742205A (zh) 组织缺氧的体液指标
Radioimmunoassays Parathyroid Hormone in Chronic Renal

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170306

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170306

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20171114

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171121

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180517

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180904

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181121

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190409

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190508

R150 Certificate of patent or registration of utility model

Ref document number: 6526577

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250